Last reviewed · How we verify
MagTrace only
At a glance
| Generic name | MagTrace only |
|---|---|
| Also known as | SPIO |
| Sponsor | Vastra Gotaland Region |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS) (PHASE2)
- Premarking of Axillary Nodes Before Start of Neoadjuvant Chemotherapy Using Magnetic Approach (NA)
- Magtrial: Magtrace® as Tracer for Sentinel Lymph Node Detection in Early Stage Epithelial Ovarian Cancer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MagTrace only CI brief — competitive landscape report
- MagTrace only updates RSS · CI watch RSS
- Vastra Gotaland Region portfolio CI